Analysts expect that Illumina, Inc. (NASDAQ:ILMN) will post $1.35 earnings per share (EPS) for the current quarter, Zacks reports. Six analysts have provided estimates for Illumina’s earnings, with the highest EPS estimate coming in at $1.47 and the lowest estimate coming in at $1.32. Illumina posted earnings of $1.44 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 6.2%. The business is expected to issue its next quarterly earnings results on Tuesday, January 29th.

On average, analysts expect that Illumina will report full-year earnings of $5.75 per share for the current fiscal year, with EPS estimates ranging from $5.72 to $5.87. For the next fiscal year, analysts forecast that the business will report earnings of $6.38 per share, with EPS estimates ranging from $6.07 to $6.83. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Illumina.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.26 by $0.26. The firm had revenue of $853.00 million for the quarter, compared to the consensus estimate of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. Illumina’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same period last year, the firm posted $1.11 EPS.

Several analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Barclays lifted their price objective on shares of Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research report on Wednesday, October 24th. BidaskClub downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Deutsche Bank boosted their price target on shares of Illumina to $350.00 and gave the stock a “buy” rating in a research report on Friday, October 12th. Finally, ValuEngine downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $330.94.

In related news, Director Robert S. Epstein sold 1,346 shares of the business’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $345.14, for a total value of $464,558.44. Following the sale, the director now directly owns 7,139 shares in the company, valued at approximately $2,463,954.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mostafa Ronaghi sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 12th. The stock was sold at an average price of $314.63, for a total transaction of $3,146,300.00. Following the completion of the sale, the senior vice president now owns 79,612 shares in the company, valued at $25,048,323.56. The disclosure for this sale can be found here. Insiders have sold a total of 63,464 shares of company stock worth $21,029,631 over the last 90 days. 0.54% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC raised its holdings in shares of Illumina by 12.3% in the 3rd quarter. Jennison Associates LLC now owns 4,826,216 shares of the life sciences company’s stock worth $1,771,511,000 after purchasing an additional 528,635 shares in the last quarter. Capital International Investors bought a new stake in shares of Illumina in the 3rd quarter worth approximately $1,482,837,000. Jackson Square Partners LLC raised its holdings in shares of Illumina by 7.7% in the 3rd quarter. Jackson Square Partners LLC now owns 1,429,221 shares of the life sciences company’s stock worth $524,609,000 after purchasing an additional 102,639 shares in the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of Illumina by 272.2% in the 3rd quarter. Canada Pension Plan Investment Board now owns 1,023,452 shares of the life sciences company’s stock worth $375,668,000 after purchasing an additional 748,500 shares in the last quarter. Finally, Fred Alger Management Inc. raised its holdings in shares of Illumina by 21.4% in the 2nd quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock worth $217,413,000 after purchasing an additional 137,302 shares in the last quarter. Institutional investors and hedge funds own 90.13% of the company’s stock.

NASDAQ:ILMN traded up $11.28 during mid-day trading on Thursday, hitting $319.51. The stock had a trading volume of 1,071,500 shares, compared to its average volume of 933,548. The company has a market cap of $45.63 billion, a PE ratio of 79.88, a P/E/G ratio of 2.30 and a beta of 1.07. Illumina has a 52 week low of $205.41 and a 52 week high of $372.61. The company has a quick ratio of 2.24, a current ratio of 2.46 and a debt-to-equity ratio of 0.24.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Article: Buyback For Investors Defined

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.